ViroMed of Korea has been given SFDA approval to begin a China Phase II clinical trial of a gene therapy drug. VM202-PAD will be tested as a treatment for Critical Limb Ischemia (CLI). The drug candidate is a biologic drug based on Hepatocyte Growth Factor (HGF), a gene that stimulates the growth of arteries. Trials of VM202-PAD for this indication are already underway in Korea and the US. More details....

Stock Symbol: (KRX: 084990)     Share this with colleagues: